|
EPC2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.56239474083486E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.26870000061174E-08 |
| Normal-vs-Stage2 |
1.08389999997627E-06 |
| Normal-vs-Stage3 |
1.2113999803276E-09 |
| Normal-vs-Stage4 |
2.20840001841083E-09 |
| Stage1-vs-Stage2 |
3.655400E-01 |
| Stage1-vs-Stage3 |
1.018230E-01 |
| Stage1-vs-Stage4 |
1.967670E-02 |
| Stage2-vs-Stage3 |
7.784800E-01 |
| Stage2-vs-Stage4 |
3.804000E-01 |
| Stage3-vs-Stage4 |
4.932200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.39570022206215E-10 |
| Normal-vs-AfricanAmerican |
5.399400E-03 |
| Normal-vs-Asian |
2.4641000000436E-06 |
| Caucasian-vs-AfricanAmerican |
2.528400E-01 |
| Caucasian-vs-Asian |
9.807600E-01 |
| AfricanAmerican-vs-Asian |
3.058400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.21220042284642E-10 |
| Normal-vs-Female |
5.25990029309753E-10 |
| Male-vs-Female |
3.198600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.96849999967164E-07 |
| Normal-vs-Age(41-60Yrs) |
2.38029995713873E-09 |
| Normal-vs-Age(61-80Yrs) |
8.79010197962771E-11 |
| Normal-vs-Age(81-100Yrs) |
7.648500E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.755600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.106300E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.852020E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.160800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.285000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.529000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.266640E-01 |
| Classical-VS-Follicular |
4.953800E-04 |
| Classical-VS-Other |
5.773200E-01 |
| Classical-VS-Normal |
2.42050000043292E-08 |
| Tall-VS-Follicular |
4.891000E-01 |
| Tall-VS-Other |
8.244800E-01 |
| Tall-VS-Normal |
7.43259999991253E-07 |
| Follicular-VS-Other |
5.732400E-01 |
| Follicular-VS-Normal |
2.54899990004276E-10 |
| Other-VS-Normal |
2.134000E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.57039944884241E-11 |
| Normal-vs-N1 |
3.12269999969139E-07 |
| N0-vs-N1 |
7.730400E-01 |
|
|
